title: Treatment of acute lymphoblastic leukemia in children with the BFM protocol: a cooperative study and analysis of prognostic factors.
authors.forename: R
authors.initials: R
authors.lastname: Maurus
authors.forename: A
authors.initials: A
authors.lastname: Boilletot
authors.forename: J
authors.initials: J
authors.lastname: Otten
authors.forename: N
authors.initials: N
authors.lastname: Philippe
authors.forename: Y
authors.initials: Y
authors.lastname: Benoit
authors.forename: C
authors.initials: C
authors.lastname: Behar
authors.forename: M
authors.initials: M
authors.lastname: Casteels-Van Daele
authors.forename: J M
authors.initials: JM
authors.lastname: Chantraine
authors.forename: M J
authors.initials: MJ
authors.lastname: Delbeke
authors.forename: J
authors.initials: J
authors.lastname: Gyselinck
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D001530:Belgium; D002648:Child; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005602:France; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D008727:Methotrexate / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D012306:Risk; D013866:Thioguanine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D001215:Asparaginase; D013866:Thioguanine; D011241:Prednisone; D008727:Methotrexate